Results 61 to 70 of about 54,594 (319)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

Frontiers in Immunology, 2023
The PD-1/PD-L1 signaling pathway plays a crucial role in cancer immune evasion, and the use of anti-PD-1/PD-L1 antibodies represents a significant milestone in cancer immunotherapy.
Tianye Li, Xinrun Wang, Mengke Niu, Mingli Wang, Jianwei Zhou, Kongming Wu, Ming Yi   +6 more
semanticscholar   +1 more source

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

FEBS Open Bio, EarlyView.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu, Hao Jiang, Limin Chen, Fulai Zhou, Ying Jin, Mark L. Chiu   +5 more
wiley   +1 more source

Antibodies to watch in 2026

mAbs
The Antibodies to Watch article series provides annual updates on commercial late-stage clinical development, regulatory review, and marketing approvals of antibody therapeutics.
Silvia Crescioli, Hélène Kaplon, Alicia Chenoweth, Yu-Shin Hsu, Kieran Pinto, Vaishali Kapoor, Janice M. Reichert   +6 more
doaj   +1 more source

Bispecific Antibodies Against HIV [PDF]

Cell, 2016
Synergistic bispecific antibodies against HIV exhibit extraordinary potency and breadth of neutralization as promising candidates for treatment and prevention.
openaire   +2 more sources

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis

Advancement of science, 2023
The majority of patients with human epidermal growth factor receptor 2 (Her2)‐positive gastric cancer develop refractory to Her2‐targeted therapy, where upregulation of immune checkpoints plays an essential role.
Wu Lin, Yingzi Zhang, Yan Yang, Ben Lin, Mengjia Zhu, Jinling Xu, Yiran Chen, Weiwei Wu, Bingliang Chen, Xiangliu Chen, Jin Liu, Haohao Wang, F. Teng, Xiongfei Yu, Haiyong Wang, Jun Lu, Quan Zhou, L. Teng   +17 more
semanticscholar   +1 more source

Impact of APOE ε4 Genotype Load on Cognitive Function and Lipid Metabolism in Patients With Cerebral Small Vessel Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Apolipoprotein ε4 (APOE ε4) is a potent genetic risk factor for Alzheimer's disease (AD). However, its role in cerebral small vessel disease (CSVD) remains unclear. Given the clinical and pathological similarities between CSVD and AD, this study aimed to investigate the associations of APOE ε4 gene dosage with cognitive function and
Tingru Jin, Haocheng Yang, Feng Liu, Sihao Lin, Junru Hu, Jian Wang, Yulan Gou   +6 more
wiley   +1 more source

Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma: a retrospective real-world study

Frontiers in Immunology
BackgroundAt the time of diagnosis, 80% of patients with pancreatic ductal adenocarcinoma (PDAC) are already at an unresectable advanced stage. The median overall survival (mOS) with traditional AG chemotherapy is only 8.5 months. The bispecific antibody
Wenke Qin, Yan Du, Xuean Zhao, Yongqing Zhao, Yan Zhang, Shuze Zhang, Zengxi Yang, Xin Li, Jubao Niu, Dewen Zhao, Kongyuan Wei, Hui Zhang, Hui Zhang   +12 more
doaj   +1 more source

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity

OncoImmunology, 2021
Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it.
Haiping Jiang, Haiqing Ni, Pan Zhang, Xiaoli Guo, Min Wu, Haoran Shen, Jie Wang, Weiwei Wu, Zhihai Wu, Jiazheng Ding, Rong Tang, Shuaixiang Zhou, Bingliang Chen, Michael Yu, Hua Jing, Junjian Liu   +15 more
doaj   +1 more source

Construction and periplasmic expression of a bispecific tandem scFv for dual targeting of immune checkpoints

Advanced Biomedical Research, 2023
Background: Immune checkpoints are molecules that act as regulators of immune system pathways. However, some tumor cells can express the ligands of immune checkpoints to escape from antitumor immune responses. Some agents, such as antibodies, can inhibit
Amirreza Rashti, Vajihe Akbari
doaj   +1 more source

Bispecific Antibodies in Hematological Malignancies: A Scoping Review

Cancers, 2023
Simple Summary Bispecific T-cell engagers (BiTEs) and bispecific antibodies (BiAbs) have emerged as novel therapeutic modalities in the treatment of advanced hematological malignancies.
Mohamed H Omer, Areez Shafqat, Omar Ahmad, K. Alkattan, Ahmed Yaqinuddin, M. Damlaj   +5 more
semanticscholar   +1 more source